Conditional survival of malignant melanoma in The Netherlands: 1994–2008
Introduction
Cutaneous malignant melanoma encompasses a large variety of malignancies with different disease presentations and short-term outcomes. Cutaneous malignant melanoma causes the majority of skin cancer related deaths and is currently the sixth most common cancer in the Netherlands (excluding keratinocyte carcinomas of the skin) with continuously increasing incidence rates of 4% annually [1]. Similar rising trends have been reported in most European countries, while Australia, New Zealand, North America and Israel showed a stabilising or declining trend (mainly youngest age groups) [2]. Norway has decreasing incidence trends in young age groups and increasing trends in older patients [3]. Mortality rates increased in the Netherlands [1] and several other European countries [4], but remained stable or decreased in Scotland, the United Kingdom, Denmark (females), Iceland (males), the United States and Australia [5], [6], [7], [8], [9], [10], [11].
Survival estimates for cancer patients are traditionally reported from the time since cancer diagnosis and do not provide estimates for patients who have already survived a period of time after initial diagnosis and treatment. Patients diagnosed with nodal or distant metastases often die soon after diagnosis and negatively affect standard survival curves which are estimated at time of diagnosis. The right side of melanoma Kaplan–Meier survival curves shows that there is generally a proportion of patients that have a better survival. The increasing incidence and relatively good survival, mostly due to thin melanomas, have resulted in a growing group of melanoma survivors. At the same time, patients with early nodal metastases (i.e. Sentinel Node (SN) positive patients), who have survived for 2–3 years after initial surgery, have a large chance to survive for a longer period of time. Conditional survival analysis is a method to estimate the survival rate of patients who already survived a certain period of time, i.e. patients on the right side of Kaplan–Meier survival curves.
These estimates give important information to cancer patients, i.e. almost a third of cancer survivors in the Netherlands experienced either changes in their work situation, problems with life insurances and/or problems regarding house mortgages due to their cancer [12]. These problems could decrease several years after diagnosis if conditional survival show trends to 100%.
Recent studies reported conditional survival estimates for melanoma in Europe [10], [13], [14], [15], Australia [16] and the United States of America (USA) [17], [18], [19], [20]. In this study, we present conditional 5-year relative survival rates for Dutch melanoma patients without nodal involvement and conditional 1-year relative survival rates for patients with and without nodal involvement, stratified for gender and Breslow thickness. This stratification is useful for caregivers and patients to be informed on their prognosis years after their initial diagnosis.
Section snippets
Data collection
For this study, population-based data was used from the nationwide Netherlands Cancer Registry (NCR), which was started in 1989 and is maintained and hosted by the Comprehensive Cancer Centres [1]. The NCR is primarily based on notification of all newly diagnosed malignancies in the Netherlands by the automated pathology archive (PALGA) [1]. Information on patient characteristics such as gender and date of birth, as well as tumour characteristics such as date of diagnosis, location
Results
A total of 40,050 patients (16,942 men and 23,108 women) were diagnosed with a stage I–III melanoma (N+: 6%, N0: 94%) between 1994 and 2010. The median ages of male and female patients were 56 (interquartile range (IQR): 44–67) and 52 (IQR: 40–65). The median (IQR) follow-up time was 5.4 (IQR: 2.8–9.4) years (males: 4.8[2.5–8.6] years, females: 5.8[3.0–9.8] years). Female patients had more thin melanomas (T1, Breslow thickness ⩽1.0 mm) compared to male patients (54% versus 44%, p < 0.0001). Thick
Discussion
Survival of patients with advanced melanoma was fairly good 5 years after diagnosis. To the best of our knowledge, this is the largest population-based study providing accurate conditional survival estimates for melanoma patients according to gender, Breslow thickness and nodal status with 1- and 5-year CRS estimates up to 15 and 11 years after diagnosis, respectively. Dutch melanoma patients who are N0 at diagnosis and still alive 5 years after diagnosis have a high probability of surviving
Contributions of all authors
R.J.T. van der Leest: Writing, study design, data interpretation, literature search; L.N. van Steenbergen: Data analysis, writing/editing, figures; L.M. Hollestein: Writing/editing manuscript, data interpretation; E. de Vries: Study design, data interpretation, writing/editing manuscript; T. Nijsten: Study design, data interpretation, editing manuscript; A.C.J. van Akkooi: Writing/editing manuscript, data interpretation; M.L.G. Janssen-Heijnen: Study design, data interpretation, writing/editing
Funding
This work was supported by the Dutch Cancer Society [Grant No. IKZ 2009-4316], project ‘Insight into health aspects of long-term cancer survivors in the Netherlands – a tool for caregivers and cancer survivors’).
Conflict of interest statement
None declared.
Acknowledgements
This research was performed within the framework of the project ‘Insight into health aspects of long-term cancer survivors in The Netherlands – a tool for caregivers and cancer survivors’ (Dutch Cancer Society Grant IKZ 2009-4316).The funding source had no involvement in data collection, data analysis and data interpretation.
We thank the registrars of The Netherlands Cancer Registry for their dedicated data collection. We thank Arjen Joosse for his critically reading of the manuscript and
References (31)
- et al.
Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
Eur J Cancer
(2008) - et al.
Incidence of and survival from malignant melanoma in Scotland: an epidemiological study
Lancet
(2002) - et al.
Trends in melanoma mortality in Australia: 1950–2002 and their implications for melanoma control
Aust N Z J Public Health
(2005) - et al.
Melanoma epidemic: facts and controversies
Clin Dermatol
(2010) - et al.
Socio-economic implications of cancer survivorship: Results from the PROFILES registry
Eur J Cancer
(2012) - et al.
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
Eur J Cancer
(2009) - et al.
Prognosis for long-term survivors of cancer
Ann Oncol
(2007) - et al.
Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis
Ann Oncol
(2006) - et al.
Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases
Eur J Cancer
(2004) - et al.
Gender differences in melanoma survival: female patients have a decreased risk of metastasis
J Invest Dermatol
(2011)
Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site
Ann Oncol
International trends in the incidence of malignant melanoma 1953–2008 – are recent generations at higher or lower risk?
Int J Cancer
Cutaneous malignant melanoma incidence rates in Norway
Scand J Public Health
Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003
Int J Cancer
Cited by (19)
Increasing time trends of thin melanomas in the Netherlands: What are the explanations of recent accelerations?
2015, European Journal of CancerCitation Excerpt :Tumour-staging classification of the American Joint Committee on Cancer staging system for melanomas was not used because the criteria were changed during the study period [12]. NX and MX were regarded as absence of lymph node and distant metastasis, respectively, as indicated by survival estimates [2,13]. The incidence rates were calculated per 100,000 person-years, using the annual midyear population size from the Statistics Netherlands (CBS, Centraal Bureau voor de Statistiek), subtracting the population size of the region of Rotterdam.
Conditional Metastasis of Uveal Melanoma in 8091 Patients over Half-Century (51 Years) by Age Group: Assessing the Entire Population and the Extremes of Age
2023, Investigative Ophthalmology and Visual ScienceSurvival in 31 670 patients with thin melanomas: a Swedish population-based study*
2021, British Journal of DermatologyConditional survival and changing risk profile in patients with chordoma: A population-based longitudinal cohort study
2019, Journal of Orthopaedic Surgery and Research